Market Research Life Sciences Market Research Pharmaceuticals Market Research Therapeutic Area Market Research Ophthalmology Market Research

Age-Related Macular Degeneration Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

Best Price Guarantee Length Publisher Published Date SKU
from $10,995 115 Pages GlobalData July, 2022 GBDT17370320
Best Price Guarantee
Price from $10,995
Length 115 Pages
Publisher GlobalData
Published Date July, 2022
SKU GBDT17370320

Age-Related Macular Degeneration Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

Summary



Macular degeneration is the breakdown of the macula, a small, oval-shaped area of the retina that is responsible for high-acuity and central vision, as well as the ability to see colors and fine details. The loss of central vision can negatively impact patient’s quality of life as everyday tasks such as reading, writing, driving, and recognizing faces and other objects becomes increasingly challenging.

Major drivers of growth in the AMD market during the forecast period include the following -

  • The launches of longer-acting anti-vascular endothelial growth factor (VEGF) therapies to treat patients with wet AMD (wAMD)
  • The availability of therapies for geographic atrophy (GA), which will increase the number of treatable cases of AMD
  • An increase in the number of people with AMD, in line with the growth of the global aging population
Major barriers to growth in the AMD market during the forecast period will include the following -
  • Increased pressure to provide evidence of drug cost-effectiveness in the 7MM, which could complicate the reimbursement process of late-stage pipeline agents
  • Products that are due to lose exclusivity within the forecast period, and the subsequent launch of biosimilars
  • The lack of dry AMD (dAMD) therapies, dampening global sales for this indication and leaving patients with this sub-indication without access to approved therapies
Key Highlights
  • AMD market will grow significantly during the forecast period, at a CAGR of 12.0%.
  • Late-stage pipeline therapies are anticipated to drive growth in the AMD market, with potential for first-to-market therapies for GA.
  • Development of cell-based and gene therapies represent a new paradigm of treatment modalities for AMD.
  • Reducing treatment burden is an important unmet need for wet AMD.
Key Questions Answered
  • What are the key unmet needs in AMD? What do KOLs identify as the key unmet needs? Will the products in the current pipeline fill these unmet needs?
  • What were the key AMD treatments in 2021?
  • When will the late stage pipeline products launch, and how will it affect drug sales and the overall AMD market in the 7MM?
Scope
  • Overview of AMD- including epidemiology, disease etiology and management.
  • Topline AMD drugs market revenue, annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
  • Key topics covered include assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5U and Japan over the 10-year forecast period.
  • Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global AMD therapeutics market. Insightful review of the key industry drivers and barriers.
Reasons to Buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global AMD therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AMD market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global AMD therapeutics market from 2021-2031.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


1 Age-Related Macular Degeneration: Executive Summary
1.1 AMD market will grow significantly during the forecast period, reaching sales of $22.8 billion in 2031
1.2 Development of cell-based and gene therapies represent a new paradigm for AMD
1.3 Reducing treatment burden is an important unmet need for wet AMD
1.4 Treatment for geographic atrophy and dry AMD represent an important unmet need for AMD
1.5 Late-stage pipeline therapies are anticipated to drive growth in the AMD market
1.6 What do physicians think?
2 Introduction
2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports
3 Disease Overview
3.1 Etiology and pathophysiology
3.2 Classification or staging systems
4 Epidemiology
4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology
4.5 Epidemiological forecast for AMD (2021-31)
4.6 Discussion
5 Disease Management
5.1 Diagnosis and treatment overview
5.2 KOL Insights on Disease Management
6 Competitive Assessment
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Longer-acting anti-VEGF therapies
7.3 Treatment for GA
7.4 Availability or accessibility of specialists and patient wait times
7.5 Less invasive drug formulations
7.6 Early diagnosis of patients and increasing awareness of AMD
8 R&D Strategies
8.1 Overview
8.2 Clinical trials design
9 Pipeline Assessment
9.1 Overview
9.2 Promising drugs in clinical development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive assessment
11 Current and Future Players
11.1 Overview
11.2 Deal-making trends
12 Market Outlook
12.1 Global markets
12.2 US
12.3 5EU
12.4 Japan
13 Appendix
13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.4 Primary research - KOLs interviewed for this report
13.5 Primary research - prescriber survey
13.6 About the authors
Contact Us
List of Tables
Table 1: AMD: key metrics in the 7MM
Table 2: Biological pathways associated with AMD risk genes
Table 3: The four-stage AREDS classification of AMD
Table 4: Symptoms of AMD
Table 5: Risk factors and comorbid conditions associated with AMD
Table 6: Treatment guidelines for AMD
Table 7: Top 10 deals by value, 2016-21
Table 8: AMD market - global drivers and barriers, 2021-2031
Table 9: Key events impacting sales for AMD in the US, 2021-2031
Table 10: AMD market - drivers and barriers in the US, 2021-2031
Table 11: Key events impacting sales for AMD in the 5EU, 2021-2031
Table 12: AMD market - drivers and barriers in the 5EU, 2021-2031
Table 13: Key events impacting sales for AMD in Japan, 2021-2031
Table 14: AMD market - drivers and barriers in Japan, 2021-2031
Table 15: High-prescribing physicians (non-KOLs) surveyed, by country
List of Figures
Figure 1: Global sales forecast by country for AMD in 2021 and 2031
Figure 2: Analysis of the company portfolio gap in AMD during the forecast period
Figure 3: Competitive assessment of recently approved and late-stage pipeline agents that GlobalData expects to be licensed for the treatment of wAMD and GA during the forecast period
Figure 4: Comparison of the eye under normal vision and severe vision loss due to AMD
Figure 5: 7MM, total prevalence of AMD, men and women, ages ≥50 years, %, 2021
Figure 6: 7MM, diagnosed prevalence of AMD, men and women, ages ≥50 years, 2021
Figure 7: 7MM, sources used and not used to forecast the total prevalent cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD
Figure 8: 7MM, sources used to forecast the total prevalent cases of GA and diagnosed prevalent cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD
Figure 9: 7MM, total prevalent cases of AMD, both sexes, ages ≥50 years, N, 2021
Figure 10: 7MM, total prevalent cases of AMD by age, both sexes, N, 2021
Figure 11: 7MM, total prevalent cases of AMD, by sex, ages ≥50 years, N, 2021
Figure 12: 7MM, total prevalent cases of early AMD, both sexes, ages ≥50 years, N, 2021
Figure 13: 7MM, total prevalent cases of late AMD, both sexes, ages ≥50 years, N, 2021
Figure 14: 7MM, total prevalent cases of late dry AMD, both sexes, ages ≥50 years, N, 2021
Figure 15: 7MM, total prevalent cases of late wet AMD, both sexes, ages ≥50 years, N, 2021
Figure 16: 7MM, total prevalent cases of GA, both sexes, ages ≥50 years, N, 2021
Figure 17: 7MM, diagnosed prevalent cases of AMD, both sexes, ages ≥50 years, N, 2021
Figure 18: 7MM, diagnosed prevalent cases of AMD by age, both sexes, N, 2021
Figure 19: 7MM, diagnosed prevalent cases of AMD, by sex, ages ≥50 years, N, 2021
Figure 20: 7MM, Diagnosed prevalent cases of early AMD, both sexes, ages ≥50 years, N, 2021
Figure 21: 7MM, diagnosed prevalent cases of late AMD, both sexes, ages ≥50 years, N, 2021
Figure 22: 7MM, diagnosed prevalent cases of late dry AMD, both sexes, ages ≥50 years, N, 2021
Figure 23: 7MM, diagnosed prevalent cases of late wet AMD, both sexes, ages ≥50 years, N, 2021
Figure 24: 7MM, diagnosed prevalent cases of GA, both sexes, ages ≥50 years, N, 2021
Figure 25: Amsler grid, as viewed by patients with normal vision and with wAMD
Figure 26: Unmet needs and opportunities in AMD
Figure 27: Overview of the development pipeline in AMD
Figure 28: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for AMD in the 7MM during the forecast period
Figure 29: Competitive assessment of recently approved agents and late-stage pipeline agents that GlobalData expects to be licensed for the treatment of wAMD and GA during the forecast period
Figure 30: Competitive assessment of the pipeline drugs benchmarked against the standard of care, Eylea
Figure 31: Analysis of the company portfolio gap in AMD during the forecast period
Figure 32: Global (7MM) sales forecast by country for AMD in 2021 and 2031
Figure 33: Sales forecast by disease subtype for AMD in the US in 2031
Figure 34: Sales forecast for GA in the US in 2031
Figure 35: Sales forecast by class for wAMD in the US in 2021 and 2031
Figure 36: Sales forecast by disease subtype in the 5EU in 2031
Figure 37: Sales forecast by class for wAMD in the 5EU in 2021 and 2031
Figure 38: Sales forecast by class for wAMD in Japan in 2021 and 2031

$10,995
$21,990
$32,985

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings